Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Duality Biotherapeutics, Inc. ( (HK:9606) ) just unveiled an update.
Duality Biotherapeutics will present updated Phase 1/2 data for its core B7-H3 antibody-drug conjugate DB-1311/BNT324 in heavily pretreated metastatic castration-resistant prostate cancer at the 2026 ASCO Genitourinary Cancers Symposium. The study, involving 104 patients across dose optimization and expansion cohorts, showed a confirmed overall response rate of 34.5%, disease control in 87.9% of response-evaluable patients and a median radiographic progression-free survival of 11.3 months, with safety dominated by mostly mild nausea and hematologic events.
Efficacy outcomes appeared consistent in patients with and without prior Lu-177 PSMA therapy, suggesting DB-1311/BNT324 may be viable across different treatment histories, though prior Lu-177 exposure was associated with shorter PSA response duration. The results support the ongoing global Phase 3 trial in taxane-naïve metastatic castration-resistant prostate cancer and reinforce the strategic value of DB-1311/BNT324 for Duality’s oncology franchise, while regulatory cautions highlight that successful development and commercialization are not guaranteed, a key consideration for investors.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates for oncology, with a particular emphasis on cancers expressing the B7-H3 protein. Its lead candidate, DB-1311/BNT324, targets multiple tumor types, including metastatic castration-resistant prostate cancer, lung cancers, breast cancer, esophageal squamous cell carcinoma and head and neck squamous cell carcinoma. The drug has received FDA Fast Track and Orphan Drug designations for certain advanced solid tumors, underscoring its strategic importance in the company’s pipeline and its potential positioning in difficult-to-treat cancer indications.
Average Trading Volume: 715,920
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$30.92B
See more insights into 9606 stock on TipRanks’ Stock Analysis page.